News
NVRO
9.74
-1.42%
-0.14
Weekly Report: what happened at NVRO last week (0715-0719)?
Weekly Report · 4d ago
Med-tech and healthcare stocks with upside during 2Q earnings - Baird
Baird analysts outlined stocks within medical technology where they see an upside during the second quarter’s earnings. Healthcare and med-tech has underperformed the broader market year-to-date. Med-tech was up 3.4% and the U.S. Health care sector was up 8.8%.
Seeking Alpha · 07/18 15:34
Nevro Is Maintained at Hold by Truist Securities
Dow Jones · 07/16 14:03
Nevro Price Target Cut to $10.00/Share From $11.00 by Truist Securities
Dow Jones · 07/16 14:03
Truist Securities Maintains Hold on Nevro, Lowers Price Target to $10
Benzinga · 07/16 13:53
Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?
Nevro Corp. (NYSE:NVRO) has US$214.8m of debt, but has more cash than debt on its balance sheet. The company has a net cash position of US$66.7m, and is in a good position to pay off its debt. Nevro has a history of losing money, and has a high debt to equity ratio. We've identified 2 warning signs with Nevro, and are looking at how risky it is.
Simply Wall St · 07/16 13:16
Beyond The Numbers: 6 Analysts Discuss Nevro Stock
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform. The company has an average price target of $10.37 for the next 12 months. 6 analysts have shared their insights on Nevro in the last three months.
Benzinga · 07/15 20:00
Nevro Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 07/15 17:19
Morgan Stanley Maintains Equal-Weight on Nevro, Lowers Price Target to $9
Benzinga · 07/15 17:08
Weekly Report: what happened at NVRO last week (0708-0712)?
Weekly Report · 07/15 09:22
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Nevro Corp. Granted inducement restricted stock unit awards covering 69,201 shares of Nevro's common stock to 17 new non-executive employees on July 7, 2024. Nevro is a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. The company's 10 kHz Therapy has impacted the lives of more than 115,000 patients globally.
PR Newswire · 07/11 20:15
Here's Why You Should Retain Nevro (NVRO) Stock for Now
NASDAQ · 07/11 17:58
Nevro Up Nearly 15%, on Pace for Largest Percent Increase Since March 2020 -- Data Talk
Dow Jones · 07/11 17:22
Nevro Is Maintained at Sell by Citigroup
Dow Jones · 07/11 01:24
Citigroup Maintains Sell on Nevro, Lowers Price Target to $8.2
Benzinga · 07/11 01:13
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024
Nevro Corp. Will release its financial results for the second quarter of 2024 after the market closes on August 6, 2024. The company will also host a conference call to discuss the financial results. Nevro is a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain.
PR Newswire · 07/09 20:15
Weekly Report: what happened at NVRO last week (0701-0705)?
Weekly Report · 07/08 09:23
Weekly Report: what happened at NVRO last week (0624-0628)?
Weekly Report · 07/01 09:23
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Nevro Corp. Granted inducement restricted stock unit awards covering 56,692 shares of Nevro's common stock to 17 new non-executive employees on June 7, 2024. Nevro is a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. The company's 10 kHz Therapy has impacted the lives of more than 115,000 patients globally.
PR Newswire · 06/28 12:30
RBC Capital Sticks to Their Hold Rating for Nevro Corp (NVRO)
TipRanks · 06/25 01:46
More
Webull provides a variety of real-time NVRO stock news. You can receive the latest news about Nevro Corp through multiple platforms. This information may help you make smarter investment decisions.
About NVRO
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.